Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety

被引：13

作者：

Reggia, Rossella ^{[1
,2
]}

Franceschini, Franco ^{[1
,2
]}

Tincani, Angela ^{[1
,2
]}

Cavazzana, Ilaria ^{[1
,2
]}

机构：

[1] Spedali Civil Brescia, Rheumatol & Clin Immunol Dept, I-25125 Brescia, Italy

[2] Univ Brescia, Brescia, Italy

来源：

JOURNAL OF RHEUMATOLOGY | 2015年 / 42卷 / 02期

关键词：

RHEUMATOID ARTHRITIS; THERAPY; ABATACEPT; SUBCUTANEOUS FORMULATION; EFFICACY; SAFETY; ACTIVE RHEUMATOID-ARTHRITIS; LONG-TERM SAFETY; PHASE IIIB; INADEQUATE RESPONSE; TRIAL; METHOTREXATE;

D O I：

10.3899/jrheum.141042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis. Methods. Fifty-one patients treated with SC ABA were included. Clinical data were obtained from clinical charts. Results. Fourteen patients relapsed and needed to return to the IV administration. Neither clinical and laboratory features nor the previous therapies were identified as risk factors for SC formulation inefficacy. Disease activity decreased after the return to IV infusions. Conclusion. SC ABA showed a risk of relapse in 27% of cases. The reinsertion of the IV administration quickly reinstated disease control.

引用

页码：193 / 195

页数：3

共 50 条

[31] SAFETY AND EFFICACY OF SUBCUTANEOUS IMPLANTABLE-CARDIOVERTER DEFIBRILLATOR IMPLANTATION: A SINGLE CENTER EXPERIENCE
Koman, Eduard
Gupta, Ashwani
Subzposh, Faiz
Tiwari, Ankur
Fontaine, John
Kusmirek, Slawomir
Kutalek, Steven
Saltzman, Heath
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A323 - A323
[32] Intravenous Colistin Use in Children: Single-Center Experience
Cagan, Eren
Soysal, Ahmet
Bakir, Mustafa
JOURNAL OF PEDIATRIC INFECTION, 2014, 8 (04): : 153 - 158
[33] Intravenous Colistin Use in Children: Single-Center Experience
Karli, Arzu
JOURNAL OF PEDIATRIC INFECTION, 2015, 9 (01): : 52 - 53
[34] Liver Safety of Vedolizumab: A Single-center Experience
Kowsika, Sree
El-Atrache, Mazen
Kaur, Nirmal
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S377 - S377
[35] Safety of subcutaneous daratumumab in the treatment of plasma-cell disorders: A single-center experience.
Kye, Jung
Seyer, Magdalena
Patel, Samit
Kim, Eun-Jeong
Hewitt, Rhonda
Liedtke, Michaela
Iberri, David Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[36] Efficacy of Subcutaneous Epoetin-Zeta on Anemia in Renal Transplant Recipients: A Single-Center Experience
Sabbatini, M.
Vitale, S.
Garofalo, G.
Torino, M.
Gallo, R.
Carrano, R.
Federico, S.
TRANSPLANTATION PROCEEDINGS, 2014, 46 (07) : 2238 - 2240
[37] EFFICACY, SAFETY AND PHARMACOKINETICS OF SUBCUTANEOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS, WITH OR WITHOUT AN INTRAVENOUS LOADING DOSE
Nash, Peter T.
Ludivico, Charles L.
Delaet, Ingrid
Qi, Keqin
Murthy, Bindu
Corbo, Michael
Kaine, Jeffrey L.
RHEUMATOLOGY, 2012, 51 : 133 - 134
[38] EFFICACY, SAFETY AND PHARMACOKINETICS OF SUBCUTANEOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS, WITH OR WITHOUT AN INTRAVENOUS LOADING DOSE
Nash, P.
Ludivico, C.
Delaet, I.
Qi, K.
Murthy, B.
Corbo, M.
Kaine, J.
INTERNAL MEDICINE JOURNAL, 2012, 42 : 12 - 12
[39] Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience
Koennecke, HC
Nohr, R
Leistner, S
Marx, P
STROKE, 2001, 32 (05) : 1074 - 1078
[40] SWITCHING INTRAVENOUS ABATACEPT AND TOCILIZUMAB TO SUBCUTANEOUS INJECTIONS DURING THE COVID-19 PANDEMIC: A FRENCH EXPERIENCE
Combier, A.
Wanono, S.
Poiroux, L.
Frantz, C.
Descamps, E.
Fogel, O.
Boisson, M.
Ayral, X.
Bottois, C.
Allanore, Y.
Avouac, J.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1364 - 1365

← 1 2 3 4 5 →